Vericel Corporation $VCEL Stock: William Blair Investment Management LLC Reduces Position

William Blair Investment Management LLC cut its position in Vericel Corporation (NASDAQ:VCEL – Free Report) by 1.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,961,248 shares of the biotechnology company’s stock after selling 31,607 shares during the period. William Blair Investment Management LLC’s holdings in Vericel were worth $78,724,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. BlackRock Inc. acquired a new stake in shares of Vericel during the second quarter worth about $360,023,000. Bank of America Corp DE purchased a new stake in Vericel in the second quarter valued at approximately $45,210,000. Dimensional Fund Advisors LP increased its holdings in Vericel by 3.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 844,755 shares of the biotechnology company’s stock worth $27,173,000 after buying an additional 29,135 shares during the period. TimesSquare Capital Management LLC acquired a new position in Vericel in the 2nd quarter worth approximately $24,463,000. Finally, Osterweis Capital Management Inc. purchased a new position in Vericel during the 2nd quarter worth approximately $17,723,000.

Wall Street Analysts Forecast Growth

VCEL has been the subject of a number of recent research reports. Truist Financial raised their price target on shares of Vericel from $52.00 to $65.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Vericel in a report on Thursday, October 29th. Wall Street Zen upgraded shares of Vericel from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 7th. TD Cowen increased their price objective on shares of Vericel from $55.00 to $58.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Finally, Canaccord Genuity Group set a $60.00 target price on shares of Vericel in a report on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $62.00.

Check Out Our Latest Report on VCEL

Vericel Stock Down 0.8%

Shares of VCEL stock traded down $0.46 on Friday, hitting $56.96. The company had a trading volume of 698,761 shares, compared to its average volume of 911,978. Vericel Corporation has a twelve month low of $28.95 and a twelve month high of $59.75. The firm has a market cap of $2.91 billion, a P/E ratio of 89.00 and a beta of 1.08. The company has a 50-day moving average price of $42.78 and a 200-day moving average price of $39.41.

Vericel (NASDAQ:VCEL – Get Free Report) last posted its earnings results on Thursday, November 5th. The biotechnology company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.06 by $0.21. The firm had revenue of $85.37 million for the quarter, compared to analyst estimates of $77.95 million. Vericel had a return on equity of 9.09% and a net margin of 10.27%. Vericel’s revenue for the quarter was up 26.5% compared to the same quarter last year. During the same period last year, the company earned $0.10 earnings per share. Equities research analysts expect that Vericel Corporation will post 0.78 EPS for the current year.

Insider Buying and Selling

In other news, CFO Joseph Mara, Jr. sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $58.26, for a total transaction of $1,456,500.00. Following the sale, the chief financial officer owned 16,186 shares of the company’s stock, valued at $942,996.36. This trade represents a 60.70% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Robert Zerbe sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $57.88, for a total transaction of $115,760.00. Following the sale, the director directly owned 32,995 shares in the company, valued at $1,909,750.60. The trade was a 5.72% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 49,008 shares of company stock worth $2,701,078. 7.60% of the stock is currently owned by company insiders.

About Vericel

(Free Report)

Vericel Corporation is a biopharmaceutical company focused on developing and commercializing cell therapies and other treatments for serious conditions. Based in Cambridge, Massachusetts, the company markets its products primarily in the United States. Its products include MACI, an implant made from a patient’s own cultured cartilage cells used to repair certain cartilage defects in the knee, and Epicel, a cultured skin graft used to treat patients with deep burns. Vericel also commercializes NexoBrid in the United States, an enzyme-based treatment for removing dead tissue from severe thermal burns.

Further Reading

Want to see what other hedge funds are holding VCEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vericel Corporation (NASDAQ:VCEL – Free Report).

Institutional Ownership by Quarter for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.